SEC Form 4 · accession 0000899243-17-017894

AILERON THERAPEUTICS INC · ALRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Director · 10% Owner

Period of report

Jul 5, 2017

Accepted (ET)

Jul 5, 2017 · 8:25 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001420565

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 5, 2017	C	285,438	—	A	295,076	D
Common Stock	Jul 5, 2017	P	159,307	$15.00	A	454,383	D
Common Stock^F2	Jul 5, 2017	P	66,666	$15.00	A	521,049	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series D Preferred Stock^F1	—	Jul 5, 2017	C	106,856	D	—	—	Common Stock	10,753	D
Series D-1 Preferred Stock^F1	—	Jul 5, 2017	C	363,636	D	—	—	Common Stock	36,594	D
Series E-2 Preferred Stock^F1	—	Jul 5, 2017	C	612,002	D	—	—	Common Stock	61,588	D
Series E-3 Preferred Stock^F1	—	Jul 5, 2017	C	1,266,130	D	—	—	Common Stock	127,415	D
Series F Preferred Stock^F1	—	Jul 5, 2017	C	487,776	D	—	—	Common Stock	49,086	D

F1The Series D, Series D-1, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series D-1, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2These shares are directly owned by Jake86 LLC, for which the Reporting Person serves as investment manager. The Reporting Person disclaims beneficial ownership of the shares held by Jake86 LLC, except to the extent of his indirect pecuniary interest therein.